Premium
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Author(s) -
Russo Roberto,
Cozzani Emanuele,
Gasparini Giulia,
Parodi Aurora
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13190
Subject(s) - bullous pemphigoid , medicine , pemphigus vulgaris , immunology , pemphigoid , monoclonal antibody , interleukin , atopic dermatitis , dupilumab , interleukin 4 receptor , interleukin 17 , receptor , monoclonal , pemphigus , immunotherapy , dermatology , cytokine , antibody , immune system
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We propose IL‐4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom